A brief history of CAR-T cells: from laboratory to the bedside

Styczyński, Jan

doi:10.2478/ahp-2020-0002

Cited by 40 publications

(38 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CAR T cells, consisting of TCR constant domains fused to variable domains of anti-2,4,6-trinitrophenyl antibody, were first generated in 1989 [ 155 ]. Since then, both the constructs (different generations) and related effectiveness of CAR T cells have improved as different generations of CAR T cells are developed and tested in the clinic [ 156 ]. The process of producing CAR T cells is complicated and includes multiple steps [ 157 ].…”

Section: Types Of Immunotherapy: Their Combinations and Limitationmentioning

confidence: 99%

Immunotherapies and Combination Strategies for Immuno-Oncology

Barbari

Fontaine

Parajuli

et al. 2020

IJMS

View full text Add to dashboard Cite

The advent of novel immunotherapies in the treatment of cancers has dramatically changed the landscape of the oncology field. Recent developments in checkpoint inhibition therapies, tumor-infiltrating lymphocyte therapies, chimeric antigen receptor T cell therapies, and cancer vaccines have shown immense promise for significant advancements in cancer treatments. Immunotherapies act on distinct steps of immune response to augment the body’s natural ability to recognize, target, and destroy cancerous cells. Combination treatments with immunotherapies and other modalities intend to activate immune response, decrease immunosuppression, and target signaling and resistance pathways to offer a more durable, long-lasting treatment compared to traditional therapies and immunotherapies as monotherapies for cancers. This review aims to briefly describe the rationale, mechanisms of action, and clinical efficacy of common immunotherapies and highlight promising combination strategies currently approved or under clinical development. Additionally, we will discuss the benefits and limitations of these immunotherapy approaches as monotherapies as well as in combination with other treatments.

show abstract

Section: Types Of Immunotherapy: Their Combinations and Limitationmentioning

confidence: 99%

Immunotherapies and Combination Strategies for Immuno-Oncology

Barbari

Fontaine

Parajuli

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…therapy [2,3,4]. So far, it is feasible only for B-cell lineage hematological malignancies, but the door has been opened for further research and progress.…”

Section: Car-t Cell Is Probably the Most Important Development In Antmentioning

confidence: 99%

Where dreams come true: CAR-T cell therapy in Poland!

Styczyński

2020

Acta Haematologica Polonica

Self Cite

View full text Add to dashboard Cite

“…CARs are recombinant receptors typically targeting surface molecules (here, cancer cell surface molecules) [ 4 ]. Generally, CARs include three main components: an extracellular antigen recognition domain of the single-chain fragment variant (scFv) region, a transmembrane domain, and an intracellular CD3ζ domain [ 5 ]. Novel CAR constructs evolve by adding co-stimulatory domains or targeting domains [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses

et al. 2022

View full text Add to dashboard Cite

Background Cancer is one of the critical issues of the global health system with a high mortality rate even with the available therapies, so using novel therapeutic approaches to reduce the mortality rate and increase the quality of life is sensed more than ever. Main body CAR-T cell therapy and oncolytic viruses are innovative cancer therapeutic approaches with fewer complications than common treatments such as chemotherapy and radiotherapy and significantly improve the quality of life. Oncolytic viruses can selectively proliferate in the cancer cells and destroy them. The specificity of oncolytic viruses potentially maintains the normal cells and tissues intact. T-cells are genetically manipulated and armed against the specific antigens of the tumor cells in CAR-T cell therapy. Eventually, they are returned to the body and act against the tumor cells. Nowadays, virology and oncology researchers intend to improve the efficacy of immunotherapy by utilizing CAR-T cells in combination with oncolytic viruses. Conclusion Using CAR-T cells along with oncolytic viruses can enhance the efficacy of CAR-T cell therapy in destroying the solid tumors, increasing the permeability of the tumor cells for T-cells, reducing the disturbing effects of the immune system, and increasing the success chance in the treatment of this hazardous disease. In recent years, significant progress has been achieved in using oncolytic viruses alone and in combination with other therapeutic approaches such as CAR-T cell therapy in pre-clinical and clinical investigations. This principle necessitates a deeper consideration of these treatment strategies. This review intends to curtly investigate each of these therapeutic methods, lonely and in combination form. We will also point to the pre-clinical and clinical studies about the use of CAR-T cell therapy combined with oncolytic viruses.

show abstract

A brief history of CAR-T cells: from laboratory to the bedside

Cited by 40 publications

References 23 publications

Immunotherapies and Combination Strategies for Immuno-Oncology

Immunotherapies and Combination Strategies for Immuno-Oncology

Where dreams come true: CAR-T cell therapy in Poland!

Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses

Contact Info

Product

Resources

About